Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
- Author
- STEWART, J. Simon W; COHEN, Ezra E. W; VARELLA-GARCIA, Marileila; GHIORGHIU, Serban; HARGREAVES, Laura; ARMOUR, Alison; SPEAKE, Georgina; SWAISLAND, Alan; VOKES, Everett E; LICITRA, Lisa; VAN HERPEN, Carla M. L; KHORPRASERT, Chonlakiet; SOULIERES, Denis; VODVARKA, Pavel; RISCHIN, Danny; GARIN, Avgust M; HIRSCH, Fred R
[1] Charing Cross Hospital, London, United Kingdom
[2] AstraZeneca, Macclesfield. Cheshire, United Kingdom
[3] AstraZeneca, Charnwood, Leicestershire, United Kingdom
[4] University of Chicago Medical Center, Chicago, IL, United States
[5] University of Colorado Health Sciences Centre at Fitzsimons, Denver, CO, United States
[6] Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
[7] Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
[8] Chulalongkorn University, Bangkok, Thailand
[9] Centre Hospitalier de l'Université de Montreal, Montreal, Canada
[10] Faculty Hospital of St Anne, Brno, Czech Republic
[11] Peter MacCallum Cancer Centre, Melbourne, Australia
[12] Cancer Research Centre, Moscow, Russian Federation - Source
Journal of clinical oncology. 2009, Vol 27, Num 11, pp 1864-1871, 8 p ; ref : 25 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- American Society of Clinical Oncology, Alexandria, VA
- Publication country
- United States
- Document type
- Article
- Language
- Russian
- Keyword (fr)
- Anticancéreux Cancer de la tête et du cou Cancérologie Carcinome épidermoïde de la tête et du cou Essai clinique phase III Etude comparative Géfitinib Méthotrexate Récidive Traitement Voie intraveineuse Antifolate Antimétabolite Cancer Dérivé de la quinazoline Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie ORL Protein-tyrosine kinase Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Head and neck cancer Cancerology Head and neck squamous cell carcinoma Phase III trial Comparative study Gefitinib Methotrexate Relapse Treatment Intravenous administration Antifolate Antimetabolic Cancer Quinazoline derivatives Enzyme Tyrosine kinase inhibitor Enzyme inhibitor ENT disease Protein-tyrosine kinase Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer de cabeza y cuello Cancerología Carcinoma epidermoideo cabeza cuello Ensayo clínico fase III Estudio comparativo Gefitinib Metotrexato Recaida Tratamiento Vía intravenosa Antifolato Antimetabólito Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima ORL patología Protein-tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B10 Otorhinolaryngology. Stomatology / 002B10A Otorhinolaryngology (head neck, general aspects and miscellaneous) / 002B10A01 Tumors
- Discipline
- Otorhinolaryngology. Stomatology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 21397459
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2008.17.0530 
https://dx.doi.org/10.1200/JCO.2008.17.0530
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.0530\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1864\";s:8:\"\u0000*\u0000epage\";s:4:\"1871\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"STEWART\";s:10:\"\u0000*\u0000aufirst\";s:10:\"J. Simon W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:16:\"COHEN, Ezra E. W\";i:1;s:25:\"VARELLA-GARCIA, Marileila\";i:2;s:17:\"GHIORGHIU, Serban\";i:3;s:17:\"HARGREAVES, Laura\";i:4;s:14:\"ARMOUR, Alison\";i:5;s:16:\"SPEAKE, Georgina\";i:6;s:15:\"SWAISLAND, Alan\";i:7;s:16:\"VOKES, Everett E\";i:8;s:13:\"LICITRA, Lisa\";i:9;s:22:\"VAN HERPEN, Carla M. L\";i:10;s:23:\"KHORPRASERT, Chonlakiet\";i:11;s:16:\"SOULIERES, Denis\";i:12;s:15:\"VODVARKA, Pavel\";i:13;s:14:\"RISCHIN, Danny\";i:14;s:15:\"GARIN, Avgust M\";i:15;s:14:\"HIRSCH, Fred R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.0530\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1864\";s:8:\"\u0000*\u0000epage\";s:4:\"1871\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"STEWART\";s:10:\"\u0000*\u0000aufirst\";s:10:\"J. Simon W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:16:\"COHEN, Ezra E. W\";i:1;s:25:\"VARELLA-GARCIA, Marileila\";i:2;s:17:\"GHIORGHIU, Serban\";i:3;s:17:\"HARGREAVES, Laura\";i:4;s:14:\"ARMOUR, Alison\";i:5;s:16:\"SPEAKE, Georgina\";i:6;s:15:\"SWAISLAND, Alan\";i:7;s:16:\"VOKES, Everett E\";i:8;s:13:\"LICITRA, Lisa\";i:9;s:22:\"VAN HERPEN, Carla M. L\";i:10;s:23:\"KHORPRASERT, Chonlakiet\";i:11;s:16:\"SOULIERES, Denis\";i:12;s:15:\"VODVARKA, Pavel\";i:13;s:14:\"RISCHIN, Danny\";i:14;s:15:\"GARIN, Avgust M\";i:15;s:14:\"HIRSCH, Fred R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.0530\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.0530\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1864\";s:8:\"\u0000*\u0000epage\";s:4:\"1871\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"STEWART\";s:10:\"\u0000*\u0000aufirst\";s:10:\"J. Simon W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:16:\"COHEN, Ezra E. W\";i:1;s:25:\"VARELLA-GARCIA, Marileila\";i:2;s:17:\"GHIORGHIU, Serban\";i:3;s:17:\"HARGREAVES, Laura\";i:4;s:14:\"ARMOUR, Alison\";i:5;s:16:\"SPEAKE, Georgina\";i:6;s:15:\"SWAISLAND, Alan\";i:7;s:16:\"VOKES, Everett E\";i:8;s:13:\"LICITRA, Lisa\";i:9;s:22:\"VAN HERPEN, Carla M. L\";i:10;s:23:\"KHORPRASERT, Chonlakiet\";i:11;s:16:\"SOULIERES, Denis\";i:12;s:15:\"VODVARKA, Pavel\";i:13;s:14:\"RISCHIN, Danny\";i:14;s:15:\"GARIN, Avgust M\";i:15;s:14:\"HIRSCH, Fred R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.0530\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1864\";s:8:\"\u0000*\u0000epage\";s:4:\"1871\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"STEWART\";s:10:\"\u0000*\u0000aufirst\";s:10:\"J. Simon W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:16:\"COHEN, Ezra E. W\";i:1;s:25:\"VARELLA-GARCIA, Marileila\";i:2;s:17:\"GHIORGHIU, Serban\";i:3;s:17:\"HARGREAVES, Laura\";i:4;s:14:\"ARMOUR, Alison\";i:5;s:16:\"SPEAKE, Georgina\";i:6;s:15:\"SWAISLAND, Alan\";i:7;s:16:\"VOKES, Everett E\";i:8;s:13:\"LICITRA, Lisa\";i:9;s:22:\"VAN HERPEN, Carla M. L\";i:10;s:23:\"KHORPRASERT, Chonlakiet\";i:11;s:16:\"SOULIERES, Denis\";i:12;s:15:\"VODVARKA, Pavel\";i:13;s:14:\"RISCHIN, Danny\";i:14;s:15:\"GARIN, Avgust M\";i:15;s:14:\"HIRSCH, Fred R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2008.17.0530\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1864\";s:8:\"\u0000*\u0000epage\";s:4:\"1871\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"STEWART\";s:10:\"\u0000*\u0000aufirst\";s:10:\"J. Simon W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:16:\"COHEN, Ezra E. W\";i:1;s:25:\"VARELLA-GARCIA, Marileila\";i:2;s:17:\"GHIORGHIU, Serban\";i:3;s:17:\"HARGREAVES, Laura\";i:4;s:14:\"ARMOUR, Alison\";i:5;s:16:\"SPEAKE, Georgina\";i:6;s:15:\"SWAISLAND, Alan\";i:7;s:16:\"VOKES, Everett E\";i:8;s:13:\"LICITRA, Lisa\";i:9;s:22:\"VAN HERPEN, Carla M. L\";i:10;s:23:\"KHORPRASERT, Chonlakiet\";i:11;s:16:\"SOULIERES, Denis\";i:12;s:15:\"VODVARKA, Pavel\";i:13;s:14:\"RISCHIN, Danny\";i:14;s:15:\"GARIN, Avgust M\";i:15;s:14:\"HIRSCH, Fred R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
